ReviewJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2020
Targeting the Dopaminergic System in Autoimmunity.
Review in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Canonical and Non-Canonical Antipsychotics' Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia.International journal of molecular sciences · 2023Pooled it
- Gastrointestinal Dopamine in Inflammatory Bowel Diseases: A Systematic Review.International journal of molecular sciences · 2021Pooled it
- Dopamine receptors in ocular surface biology: Current evidence and future directions.Indian journal of ophthalmology · 2026Review
- Indole dysbiosis and mucosal inflammation.Microbiota and host · 2025Article
- Somatic comorbidities and health related uncertainty among Swedish adolescents with ADHD.Frontiers in psychiatry · 2025Article
- Chemokinergic and Dopaminergic Signalling Collaborates through the Heteromer Formed by CCR9 and Dopamine Receptor D5 Increasing the Migratory Speed of Effector CD4International journal of molecular sciences · 2024Article
- B cells and the stressed brain: emerging evidence of neuroimmune interactions in the context of psychosocial stress and major depression.Frontiers in cellular neuroscience · 2024Review
- SARS-CoV-2 induced vitamin D deficiency and psychological stress: a manifestation of autoimmune disease onset.Frontiers in immunology · 2024Article
- Inflammation, Dopaminergic Brain and Bilirubin.International journal of molecular sciences · 2023Review
- Article
- Cold stress induces colitis-like phenotypes in mice by altering gut microbiota and metabolites.Frontiers in microbiology · 2023Article
- Article
- Dopamine receptor 1 expressing B cells exert a proinflammatory role in female patients with rheumatoid arthritis.Scientific reports · 2022Article
- Polydopamine Nanoparticle-Mediated Dopaminergic Immunoregulation in Colitis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Continuous Activation of Dopamine Receptors Alleviates LPS-Induced Liver Injury in Mice via β-arrestin2 Dependent Akt/NF-κB Pathway.Frontiers in pharmacology · 2022Article
- The Dopamine Gene Receptors (DRDRecent advances in inflammation & allergy drug discovery · 2022Article
- Dopaminergic stimulation leads B-cell infiltration into the central nervous system upon autoimmunity.Journal of neuroinflammation · 2021Article
- Dopaminergic Receptors as Neuroimmune Mediators in Experimental Autoimmune Encephalomyelitis.Molecular neurobiology · 2021Article
- Review
- Dopaminergic signalling limits suppressive activity and gut homing of regulatory T cells upon intestinal inflammation.Mucosal immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dopamine has emerged as a fundamental regulator of inflammation. In this regard, it has been shown that dopaminergic signalling pathways are key players promoting homeostasis between the central nervous system and the immune system. Dysregulation in the dopaminergic system affects both innate and adaptive immunity, contributing to the development of numerous autoimmune and inflammatory pathologies. This makes dopamine receptors interesting therapeutic targets for either the development of new treatments or repurposing of already available pharmacological drugs. Dopamine receptors are broadly expressed on different immune cells with multifunctional effects depending on the dopamine concentration available and the pattern of expression of five dopamine receptors displaying different affinities for dopamine. Thus, impaired dopaminergic signalling through different dopamine receptors may result in altered behaviour of immunity, contributing to the development and progression of autoimmune pathologies. In this review we discuss the current evidence involving the dopaminergic system in inflammatory bowel disease, multiple sclerosis and Parkinson's disease. In addition, we summarise and analyse the therapeutic approaches designed to attenuate disease development and progression by targeting the dopaminergic system. Graphical Abstract Targetting the dopaminergic system in autoimmunity. Effector T-cells (Teff) orchestrate inflamamtion involved in autoimmunity, whilst regulatory T-cells (Tregs) suppress Teff activity promoting tolerance to self-constituents. Dopamine has emerged as a key regulator of Teff and Tregs function, thereby dopamine receptors have becoming important therapeutic targets in autoimmune disorders, especially in those affecting the brain and the gut, where dopamine levels strongly change with inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.